Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis

BACKGROUND: Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a single clinical trial. OBJECTIVE: To conduct a sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuenca, John A., Balda, Javier, Palacio, Ana, Young, Larry, Pillinger, Michael H., Tamariz, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378016/
https://www.ncbi.nlm.nih.gov/pubmed/30863448
http://dx.doi.org/10.1155/2019/1076189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378016/
https://www.ncbi.nlm.nih.gov/pubmed/30863448
http://dx.doi.org/10.1155/2019/1076189

Ejemplares similares